| This cheap biotech offers investors a play on ALS if trial data continues to impress | 07/02 12:34 | marketwatch.com |
| FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen | 06/26 14:01 | zacks.com |
| Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock? | 06/25 07:30 | zacks.com |
| Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed | 06/25 06:55 | prnewswire.com |
| Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug | 06/19 13:15 | zacks.com |
| Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema | 06/18 07:00 | prnewswire.com |
| Ionis to present at TD Cowen Genetic Medicines & RNA Summit | 06/17 16:09 | prnewswire.com |
| Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema | 05/31 07:00 | prnewswire.com |
| Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism | 05/28 16:39 | seekingalpha.com |
| Ionis to hold donidalorsen Phase 3 data webcast | 05/28 07:00 | prnewswire.com |